Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Payables (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Payables data on record, last reported at $42.0 million in Q4 2025.

  • For Q4 2025, Payables changed N/A year-over-year to $42.0 million; the TTM value through Dec 2025 reached $42.0 million, changed N/A, while the annual FY2025 figure was $42.0 million, N/A changed from the prior year.
  • Payables reached $42.0 million in Q4 2025 per RCUS's latest filing, roughly flat from $42.0 million in the prior quarter.
  • Across five years, Payables topped out at $42.0 million in Q3 2025 and bottomed at $10.0 million in Q4 2021.
  • Average Payables over 5 years is $20.3 million, with a median of $17.0 million recorded in 2023.
  • Peak YoY movement for Payables: skyrocketed 911.71% in 2021, then crashed 45.41% in 2023.
  • A 5-year view of Payables shows it stood at $10.0 million in 2021, then soared by 100.0% to $20.0 million in 2022, then dropped by 15.0% to $17.0 million in 2023, then fell by 23.53% to $13.0 million in 2024, then skyrocketed by 223.08% to $42.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $42.0 million in Q4 2025, $42.0 million in Q3 2025, and $22.0 million in Q1 2025.